

Huilin Tang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5178949/publications.pdf>

Version: 2024-02-01

47
papers

1,561
citations

304743
22
h-index

315739
38
g-index

48
all docs

48
docs citations

48
times ranked

2430
citing authors

#	ARTICLE	IF	CITATIONS
1	Are novel glucose-lowering agents' cardiorenal benefits generalizable to individuals of Black race? A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment. Diabetes, Obesity and Metabolism, 2022, 24, 154-159.	4.4	5
2	Association between novel Glucose-Lowering drugs and risk of Asthma: A network Meta-Analysis of cardiorenal outcome trials. Diabetes Research and Clinical Practice, 2022, 183, 109080.	2.8	12
3	Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials. Diabetes Care, 2022, 45, 1007-1012.	8.6	4
4	Newer glucose-lowering drugs and risk of dementia: A meta-analysis of cardiovascular outcome trials. Journal of the American Geriatrics Society, 2022, 70, 2719-2722.	2.6	4
5	Red Hair Color Is Associated with Elevated CRP Levels among US Women. Journal of Investigative Dermatology, 2021, 141, 1342-1344.	0.7	1
6	Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data. International Journal of Clinical Pharmacy, 2021, 43, 1116-1122.	2.1	10
7	Effects of sodium-glucose cotransporter 2 inhibitors on risk of venous thromboembolism in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes/Metabolism Research and Reviews, 2020, 36, e3174.	4.0	8
8	Autoantibody and autism spectrum disorder: A systematic review. Research in Autism Spectrum Disorders, 2020, 75, 101568.	1.5	13
9	Effects of sodium glucose cotransporter 2 inhibitors on risk of dyslipidemia among patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Pharmacoepidemiology and Drug Safety, 2020, 29, 582-590.	1.9	13
10	Effect of short-term vitamin D supplementation after nonsurgical periodontal treatment: A randomized, double-masked, placebo-controlled clinical trial. Journal of Periodontal Research, 2020, 55, 354-362.	2.7	29
11	Pancreatic safety of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Pharmacoepidemiology and Drug Safety, 2020, 29, 161-172.	1.9	21
12	The Potential of Glycyrrhizinate in the Management of COVID-19: A Systematic Review of the Efficacy and Safety of Glycyrrhizin Preparations in the Treatment of SARS and MERS. The American Journal of Chinese Medicine, 2020, 48, 1539-1552.	3.8	9
13	Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults. Diabetes Care, 2019, 42, 2065-2074.	8.6	8
14	Assessing the Association Between Dipeptidyl Peptidase 4 Inhibitor Use and Inflammatory Bowel Disease Through Drug Adverse Event Reporting. Diabetes Care, 2019, 42, e89-e91.	8.6	6
15	Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials. Diabetes Care, 2019, 42, e119-e121.	8.6	18
16	Voriconazole exposure and risk of cutaneous squamous cell carcinoma among lung or hematopoietic cell transplant patients: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2019, 80, 500-507.e10.	1.2	30
17	Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System. Diabetes Care, 2019, 42, e21-e23.	8.6	17
18	Development and validation of an algorithm to identify drug-induced anaphylaxis in the Beijing Pharmacovigilance Database. International Journal of Clinical Pharmacy, 2018, 40, 862-869.	2.1	7

#	ARTICLE	IF	CITATIONS
19	Pioglitazone and bladder cancer risk: a systematic review and meta-analysis. <i>Cancer Medicine</i> , 2018, 7, 1070-1080.	2.8	91
20	SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1972-1976.	4.4	31
21	Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1262-1279.	4.4	44
22	Use of antihypertensive drugs and risk of keratinocyte carcinoma: A meta-analysis of observational studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 279-288.	1.9	30
23	Use of Antihypertensive Drugs and Risk of Malignant Melanoma: A Meta-analysis of Observational Studies. <i>Drug Safety</i> , 2018, 41, 161-169.	3.2	20
24	Drug-induced anaphylaxis in China: a 10-year retrospective analysis of the Beijing Pharmacovigilance Database. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 1349-1358.	2.1	25
25	Effects of Vitamin D Supplementation on Glucose and Insulin Homeostasis and Incident Diabetes among Nondiabetic Adults: A Meta-Analysis of Randomized Controlled Trials. <i>International Journal of Endocrinology</i> , 2018, 2018, 1-9.	1.5	34
26	Traditional Chinese medicine and drug-induced anaphylaxis: data from the Beijing pharmacovigilance database. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 921-927.	2.1	15
27	Meta-analysis of the association between sodium-glucose co-transporter-2 inhibitors and risk of skin cancer among patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2919-2924.	4.4	10
28	Clinical features and treatment of pediatric patients with drug-induced anaphylaxis: a study based on pharmacovigilance data. <i>European Journal of Pediatrics</i> , 2018, 177, 145-154.	2.7	25
29	Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: <scp>A</scp> network and cumulative meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1106-1115.	4.4	64
30	Cancer risk in the EMPA-REG OUTCOME trial. Reply to Shaikh AMY [letter] and Kohler S, Lee J, George JT et al [letter]. <i>Diabetologia</i> , 2017, 60, 2538-2539.	6.3	2
31	Use of Epinephrine in Patients with Drug-Induced Anaphylaxis: An Analysis of the Beijing Pharmacovigilance Database. <i>International Archives of Allergy and Immunology</i> , 2017, 173, 51-60.	2.1	16
32	SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. <i>Diabetologia</i> , 2017, 60, 1862-1872.	6.3	134
33	Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 480-488.e9.	1.2	13
34	Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 348-355.	4.4	160
35	Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 142-147.	4.4	56
36	Statin use and non-melanoma skin cancer risk: a meta-analysis of randomized controlled trials and observational studies. <i>Oncotarget</i> , 2017, 8, 75411-75417.	1.8	16

#	ARTICLE	IF	CITATIONS
37	Dopamine agonists for preventing ovarian hyperstimulation syndrome. The Cochrane Library, 2016, 11, CD008605.	2.8	20
38	Adverse effects of incretinâ€based therapies on major cardiovascular and arrhythmia events: metaâ€analysis of randomized trials. Diabetes/Metabolism Research and Reviews, 2016, 32, 843-857.	4.0	25
39	Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2016, 118, 1774-1780.	1.6	63
40	Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials. Diabetologia, 2016, 59, 2546-2551.	6.3	95
41	Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis. European Journal of Clinical Pharmacology, 2016, 72, 1185-1193.	1.9	46
42	Effect of Sodiumâ€Glucose Cotransporter 2 Inhibitors on Diabetic Ketoacidosis Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials. Diabetes Care, 2016, 39, e123-e124.	8.6	56
43	Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis. Drugs, 2016, 76, 343-361.	10.9	22
44	Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2016, 71, 1772-1785.	3.0	118
45	Effects of Fluroquinolones in Newly Diagnosed, Sputum-Positive Tuberculosis Therapy: A Systematic Review and Network Meta-Analysis. PLoS ONE, 2015, 10, e0145066.	2.5	24
46	Effect of follicle-stimulating hormone receptor Asn680Ser polymorphism on the outcomes of controlled ovarian hyperstimulation: an updated meta-analysis of 16 cohort studies. Journal of Assisted Reproduction and Genetics, 2015, 32, 1801-1810.	2.5	38
47	Effect of critical care pharmacist's intervention on medication errors: A systematic review and meta-analysis of observational studies. Journal of Critical Care, 2015, 30, 1101-1106.	2.2	53